Filing Flows › Health Care › Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks Holdings (DNA) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Ginkgo Bioworks Holdings (DNA) Q2 2026 earnings results →
Q2 2026 Revenue down 48% year over year to $20.2M · 232¢ of every $1 of revenue lost · operating margin -290.5%
Ginkgo Bioworks Holdings made $20.2M in Q2 2026 (-48% Y/Y). Operating margin -290.5%, net loss $46.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $20.2M in Q2 2026, down 48% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $58.5M, an operating margin of -290.5%. Total costs fell 19% while revenue fell 48%. The quarter ended with a net loss of $46.7M, narrower than the previous quarter's $82.6M loss. Non-operating items added $12.0M, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$44.3M. Non-cash charges added back $12.3M of depreciation and amortization and $7.6M of share-based compensation. Working capital and other items used $17.5M. Capital expenditures of $2.6M exceeded it, leaving free cash flow of −$46.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 6, 2026 | $20.2M | -48% | -290.5% | −$46.7M | −$44.3M |
| Q1 2026 | 10-Q | May 7, 2026 | $19.5M | -49% | -366.5% | −$82.6M | −$46.7M |
| Q4 2025 | 10-K | Feb 26, 2026 | $33.4M | -24% | -211.9% | −$80.8M | −$47.7M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $38.8M | -56% | -231.8% | −$80.8M | −$31.6M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $49.6M | -12% | -132.1% | −$60.3M | −$40.3M |
| Q1 2025 | 10-Q | May 6, 2025 | $48.3M | +27% | -184.1% | −$91.0M | −$51.5M |
| Q4 2024 | 10-K | Feb 25, 2025 | $43.8M | +26% | -236.3% | −$108M | −$42.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Ginkgo Bioworks Holdings
Unless the context otherwise requires, all references in this section to the “Company,” “Ginkgo,” “we,” “us,” or “our” refer to the business of Ginkgo Bioworks Holdings, Inc. and our subsidiaries. Our mission is to make biology easier to engineer. That has never changed. Every choice we’ve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.
In its own words, from its 10-K, filed Feb 26, 2026.
Ginkgo Bioworks Holdings against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -48% against the peers' median +11%. Operating margin: -290.5% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings | Q2 2026 | $20.2M | -48% | -290.5% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Ginkgo Bioworks Holdings 10-Q on SEC EDGAR · CIK 1830214 · Biological Products, (No Diagnostic Substances)
13F: who owns DNA and who is buying
More on DNA
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results